🔗 Share this article

Given that America proceeds with unprecedented adjustments to its immunization recommendations, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines during the global health crisis and has zeroed in on possible fatalities following COVID-19 immunization in her recent time at the FDA.

Planned Overhauls to Pediatric Immunization Program

Public health authorities had intended to announce major revisions to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, it is understood – a major change that would place the US out of step with many the global community with no evidence for benefit. The announcement has been pushed back until the coming year.

In place of Vinay Prasad, Høeg is scheduled to present at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood immunization guidelines in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccination policy – usually the purview of Prasad, head of the FDA’s CBER – instead of drug regulation.

Questions Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, regulation or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in industry regulation.”

Past heads of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who led CBER have had.”

The drug center has an vast portfolio at the agency, Woodcock emphasized.

“Everybody just pays attention on the innovative therapies, but the generic program approves thousands of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these must be managed,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a substantial administrative element to the job, which oversees in excess of 5,000 staff members. “It’s a huge administrative position, if you do it right,” Woodcock added.

Official Statement and Controversial Policies

In response to inquiries about Høeg’s qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a representative responded that the “concerns stem from incorrect presumptions”.

“This background is consistent with the duties of her role,” the official stated, noting the period Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day therapy clearance system that allegedly concerned her former heads. “How are these drugs being selected for this expedited pathway? Who is making the calls?” Howard asked. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent rules of all drugs, with the exception of vaccines.”

Documented History on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, past, some experts have noted. She authored a research paper using non-validated volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the incoming administration featured revising regulations for novel immunizations and ending “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has according to sources floated the idea of excluding teenage boys from obtaining Covid vaccines.

“She’s an thorough dogmatist who begins with her conclusions and reverse-engineers to retrofit the science in a extremely disingenuous, fraudulent way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|